Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 191-204 , June 2000

Tumour vasculature as a target for anticancer therapy

References 

    REFERENCES
  1. Folkman J. Anti-angiogenesis: neconcept for therapy of solid tumours. Ann Surg. 1972;175:409–416
  2. Folkman J. What is the evidence that tumours are angiogenesis dependent?. JNCI. 1990;82:4–6
  3. Gasparini G, Weidner N, Bevilaqua P, Maluta S, Dalla Palma P, Caffo O. Tumour microvessel density, p53 expression, tumour size and peritumoural lymphatic vessel invasion are relevant prognostic markers in node negative breast carcinoma. J Clin Oncol. 1994;12:454–466
  4. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neo-vascularisation to metastasis of non-small cell lung cancer. Lancet. 1992;340:145–146
  5. Olvarez D, Ulbright T, DeReise W. Neovascularisation in clinical stage A testicular germ cell tumour: prediction of metastatic disease. Cancer Res. 1994;54:2800–2802
  6. Srivastava S, Laidler P, Davies RP, Horgan K, Hughes L. The prognostic significance of tumour vascularity in intermediate thickness (0.76–4.0 mm thick) skin melanoma. Am J Path. 1988;133:419–423
  7. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Path. 1993;143:401–409
  8. Bicknell, R. Lewis, C. E. Ferrara, N. Tumour Angiogenesis, Oxford, Oxford University Press, 1997
  9. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast cancer. Cancer Res. 1996;56:4625–4629
  10. Leung DW, Cachiannes G, Kuang W-J, Goedell GD, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309
  11. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ. Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470–1478
  12. Philips GD, Stone AM, Jones BD, Schultz JC, Whitehead RA. Vascular endothelial growth factor (rhVEGF 165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1995;8:964–970
  13. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Different Devel. 1990;32:319–331
  14. Rifkin DB, Moscatelli D, Bizic J, Quarto N, Blei F, Dennis P. Growth factor control of extracellular proteolysis. Cell Different Devel. 1990;32:313–318
  15. Tolnay E, Wiethege T, Kuhnen C, Wulf M, Voss B, Muller KM. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. J Cancer Res Clin Oncol. 1997;123:652–658
  16. Zucker S, Mirza H, Conner CE. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 1998;75:780–786
  17. Shweiki DT, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia induced angiogenesis. Nature. 1992;359:843–845
  18. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 1998;58:392–395
  19. Joseph I, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3:2507–2511
  20. Scott PAE, Gleadle JM, Bicknell R, Harris AL. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer. 1998;75:706–712
  21. Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer. 1998;79:34–38
  22. Crew JP, O’Brien T, Bradburn M. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5285
  23. Hartenbach EM, Olson TA, Goswitz JJ. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial overian carcinomas. Cancer Letters. 1997;121:169–175
  24. Heits F, Katschinski DM, Wiedemann GJ, Weiss C, Jelkmann W. Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients. Int J Oncol. 1997;10:333–337
  25. Maeda K, Chung YS, Ogawa Y. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer. 1996;73:884–888
  26. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol. 1995;6:1059–1062
  27. Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol. 1998;12:1013–1018
  28. Salven P, Maenpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997;3:647–651
  29. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrarra N. Regulation by vascular endothelial growth factor expression of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95:1789–1797
  30. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 1998;35:1–10
  31. Moscatelli D, Presta M, Rifkin DB. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production. Proc Natl Acad Sci USA. 1986;83:2091–2095
  32. Gospodarowic D, Neufeld G, Schweigerer L. Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl. 1987;5:15–26
  33. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993;69:508–517
  34. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K. Identification of angiogenic acivity and the cloning and expression of platelet derived endothelial cell growth factor. Nature. 1989;338:557–562
  35. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K. Angiogenic activity of enzymes. Nature. 1994;368:198
  36. Fox SB, Westwood M, Moghaddam A. The angiogenic factor platelet-dervied endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer. 1996;73:275–280
  37. Giatromanolaki A, Koukourakis MI, Kakolyris S. Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Res. 1998;18:71–76
  38. Igarashi M, Dhar DK, Kubota H, Yamamoto A, El-Assal O, Nagasue N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer. 1998;82:1225–1232
  39. Maeda K, Kang SM, Ogawa M. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer. 1997;74:545–550
  40. O’Brien TS, Fox SB, Dickinson AJ. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 1996;56:4799–4804
  41. Tanigawa N, Amaya H, Matsumura M. Tumor angiogenesis and expression of thymidine phosphorylase/ platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Letters. 1996;108:281–290
  42. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 1995;64:79–82
  43. Amaya H, Tanigawa N, Lu C. Association of vascular endothelial growth factor expression with tumorangiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Letters. 1997;119:227–235
  44. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expressio n is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Path. 1997;182:414–420
  45. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3for angiogenesis. Science. 1994;264:569–571
  46. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500–1502
  47. Nip J, Shibata H, Loskutoff DJ, Cheresh DA, Brodt P. Human melanoma cells derived from lymphatic metastases use integrin αvβ3to adhere to lymph node vitronectin. J Clin Invest. 1992;90:1406–1413
  48. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Ruoslahti E, Hendrix MJC. Role of the αvβ3inegrin in human melanoma cell invasion. Proc Natl Acad Sci USA. 1992;89:1557–1561
  49. Pasqualini R, Borodova J, Ye S, Hemler ME. A study of the structure, function and distribution of β5intergrins using novel anti-β5monoclonal antibodies. J Cell Sci. 1993;105:101–111
  50. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997;99:1390–1398
  51. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391–400
  52. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715
  53. Pasqualini R, Koivunen E, Ruoslahti E. alpha v Integrins as receptors for tumor targeting by circulating ligands. Nature Biotech. 1997;15:542–546
  54. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377–380
  55. Rabb H, Barroso-Vicens E, Adams R, Pow-Sang J, Ramirez G. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol. 1996;16:402–408
  56. Max R, Gerritsen R, Nooijen P. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 1997;71:320–324
  57. Dirix LY, Vermeulen PB, Pawinski A. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997;76:238–243
  58. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res. 1997;3:2451–2458
  59. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79:144–146
  60. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood. 1997;90:3167–3172
  61. Kopec JA, Abrahamowicz M, Easdaile JM. Randomised discontinuation trials; utility and efficiency. J Clin Epidemiol. 1993;46:959–971
  62. Kuasaka M, Sudo K, Matsutani E. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-470). Br J Cancer. 1994;69:212–216
  63. Antoine N, Greimers R, De Roanne C. AGM-470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. 1994;54:2073–2076
  64. Abe J, Zou W, Takuwa N. Fumagillin derivative angiogenesis inhibitor, AGM-470, inhibits the activation of cyclin dependent kinases and phosphorylation of retinoblastoma gene product but not tyrosyl phosphorylation or proto-oncogene expression in endothelial cells. Cancer Res. 1994;54:3407–3412
  65. Bernsen HJ, Rijken PF, Peters H, Bakker H, van der Kogel AJ. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neuro-Oncol. 1998;38:51–57
  66. Futami H, Iseki H, Egawa S, Koyama K, Yamaguchi K. Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470. Invasion, Metastasis. 1996;16:73–82
  67. Ikebe T, Yamamoto T, Kubo S. Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogen-induced hepatic nodules in rats. Jap J Cancer Res. 1998;89:143–149
  68. Kanai T, Konno H, Tanaka T. Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. Int J Cancer. 1997;71:838–841
  69. Miki T, Nonomura N, Nozawa M. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line [see comments]. J Urol. 1998;160:210–213
  70. Morita T, Shinohara N, Tokue A. Antitumour effect of a-synthetic analogue of fumagillin on murine renal carcinoma. Br J Urol. 1994;74:416–421
  71. Sasaki A, Alcalde RE, Nishiyama A. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res. 1998;58:462–467
  72. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res. 1993;53:4262–4267
  73. Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res. 1998;58:3751–3756
  74. Dezube BJ, Von Roenn JH, Holden-Wiltse J. Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol. 1998;16:1444–1449
  75. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 [letter]. New Engl J Med. 1998;338:991–992
  76. Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res. 1997;17:71–75
  77. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res. 1997;57:1829–1834
  78. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer. 1998;77:1761–1767
  79. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995;108:2655–2661
  80. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest. 1995;96:1815–1822
  81. Mitjans F, Sander D, Adan J. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci. 1995;108:2825–2838
  82. Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, Luk HN. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. Biochem Biophys Acta. 1997;1336:445–454
  83. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58:1048–1051
  84. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem. 1998;273:5400–5404
  85. Taraboletti G, Garofalo A, Belotti D. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. JNCI. 1995;87:293–298
  86. Valente P, Fassina G, Melchiori A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998;75:246–253
  87. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. JNCI. 1995;87:1546–1550
  88. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995;55:3629–3633
  89. Nemunaitis J, Poole C, Primrose J. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998;4:1101–1109
  90. Wojtowicz-Praga S, Torri J, Johnson M. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150–2156
  91. Jones PH, Elliot M, Dobbs N. Phase I/II study of combination anti-angiogenesis therapy with marimastat, captopril and fragmin. Br J Cancer. 1999;80 (Suppl 2):3
  92. Webber MM, Waghray A. Urokinase mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res. 1995;1:755–761
  93. Narla RK, Liu XP, Klis D, Uckun FM. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxylphenyl)-amino-6,7-dimethoxyquniazoline (WHI-P131) and 4-(3′-bromo-4′-hydroxylphenyl)-amino-6, 7-dimehtoxy quinazo line (WHI-P154). Clin Cancer Res. 1998;4:3331–3338
  94. Mishima T, Murata J, Toyoshima M. Inhibition of tumour invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. Clin Experiment Met. 1998;16:541–550
  95. Gerber HP, McMurtrey A, Kowalski J. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336–30343
  96. Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Phys. 1999;276:535–542
  97. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998;95:9349–9354
  98. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 1995;10:135–147
  99. Olofsson B, Korpelainen E, Pepper MS. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA. 1998;95:11709–11714
  100. Fong TA, Shawver LK, Sun L. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99–106
  101. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1978;91:4082–4085
  102. Marx GM, Levi JA, Bell DR. A phase I/II trial of thalidomide as an anti-angiogenic agent in the treatment of advanced cancer. Proc Am Soc Clin Oncol. 1999;18:1751
  103. O’Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exs. 1997;79:273–294
  104. O’Reilly MS, Boehm T, Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285
  105. Dhanabal M, Ramchandran R, Waterman MJ. Endostatin: induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721–11726
  106. Kakej Y, Teicher BA. Pre-clinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Inv New Drugs. 1997;15:39–48
  107. Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatih administration along with an triangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol. 1998;41:497–504
  108. Belotti D, Vergani V, Borsotti P. The microtubule affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849
  109. O’Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camopthecin analogues 9-amino-20(S)-campothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999;5:181–187
  110. Cassidy J, Duncan R, Morrison GJ. Activity of N-(2-hydroxypropyl) mathecrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol. 1989;38:875–879
  111. Steyger PS, Baban DF, Brereton M, Ulbrich K, Seymour LW. Intratumoral distribution as a determinant of tumor responsiveness to therapy using polymer-based macromolecular prodrugs. J Contr Rel. 1996;39:35–46
  112. Vasey PA, Kaye SB, Morrison R. Phase I clinical and pharmacokinetic study of PK1 (HPMA Co-polymer doxorubicin): first member of a new class of chemotherapeutic agents. Clin Cancer Res. 1999;5:83–94
  113. Stastny M, Rihova B, Strohalm J, Ulbrich K. Comparison of the binding-kinetics of antibody-targeted n-(2-hydroxypropyl) methacrylamide (hpma)-bound doxorubicin in-vitro and in-vivo. J Contr Rel. 1996;42:229–236
  114. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21 expression by vascular cell integrin αvβ3during angiogenesis. J Clin Invest. 1996;98:426–433
  115. Buckley CD, Pilling D, Henriquez NV. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999;397:534–539
  116. Cao Y, O’Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998;101:1055–1063

PII: S0305-7372(99)90158-5

doi: 10.1053/ctrv.1999.0158

Cancer Treatment Reviews
Volume 26, Issue 3 , Pages 191-204 , June 2000

Article Tools